El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Regeneron Pharmaceuticals Inc
Cerrado
SectorSalud
744.45 -1.9
Resumen
Variación precio
24h
Mínimo
733.93
Máximo
758.7
Ingresos | -615M 845M |
|---|---|
Ventas | 130M 3.9B |
P/B Media del Sector | 18.248 57.833 |
BPA | 11.44 |
Rentabilidad por dividendo | 0.47 |
Margen de beneficio | 21.744 |
Empleados | 15,410 |
EBITDA | -718M 1.2B |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 meses | +15.02% upside |
Rentabilidad por dividendo Media del Sector | 0.47% 2.47% |
|---|---|
Próximas Ganancias | 28 abr 2026 |
Capitalización de Mercado | -811M 80B |
|---|---|
Apertura anterior | 746.35 |
Cierre anterior | 744.45 |
Noticias sobre sentimiento de mercado
By Acuity
21%
79%
40 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Very Strong Bearish Evidence
Regeneron Pharmaceuticals Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Regeneron Pharmaceuticals Inc Esperado
Precio Objetivo
By TipRanks
15.02% repunte
Estimación a 12 meses
Media 873.05 USD 15.02%
Máximo 1,057 USD
Mínimo 742 USD
De acuerdo con 23 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Regeneron Pharmaceuticals Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
40 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Coyuntura alcista notoria
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Live chat